Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/13/2008

in part by lower legal fees.

Jazz Pharmaceuticals' unrestricted cash, cash equivalents and marketable securities balance as of December 31, 2007 was $102.9 million. Net operating cash used during the year ended December 31, 2007 was $81.1 million.

Recent Highlights

-- On January 31, 2008, Jazz Pharmaceuticals announced that the U.S. Food

and Drug Administration (FDA) had accepted for review the submission of

the response by Solvay Pharmaceuticals, Inc. to the FDA approvable

letter for LUVOX CR. The FDA notified Solvay Pharmaceuticals that it

considered this a complete, class 1 response and the PDUFA action date

is February 29, 2008. In an approvable letter received on

December 21, 2007, the FDA had requested additional information

concerning a chemistry, manufacturing and control (CMC) issue. The

approvable letter did not raise any questions related to safety or

efficacy of LUVOX CR and included the FDA's proposed labeling. Jazz

Pharmaceuticals and Solvay Pharmaceuticals believe that the response

submitted to the FDA on December 28, 2007 fully addressed that CMC

issue.

-- Jazz Pharmaceuticals has completed the expansion of its sales force,

and now has a total of approximately 200 field sales personnel,

including sales management and sales representatives. These

individuals are currently in their assigned sales territories promoting

Xyrem.

-- In early January 2008, Jazz Pharmaceuticals announced that it had

received orphan drug designation from the FDA for its JZP-8 product

candidate for the treatment of recurrent acute repetitive seizures.

JZP-8 is a novel drug delivery formulation incorporating clonazepam, a

widely prescribed benzodiazepine. The product candidate is designed to

be a fast-acting intranasal spray for the treatment of re
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Back in the 1970’s, many companies calculated their office ... included space for circulation and file storage. “It was ... Nidea Corporate Real Estate / ITRA Global , a ... however, 250 square feet per employee became the norm. ... 175 to 225 square feet, and over the next few ...
(Date:9/29/2014)... of diagnostics today, with imaging techniques like MRI ... NMR (nuclear magnetic resonance) increasing steeply over the ... resolution and quality still limit these techniques because ... is hyperpolarization, which involves injecting the patient with ... the distribution and fate of specific molecules in ...
(Date:9/29/2014)... Research and Markets  has announced the ... & Services, End-User , Application - Global Forecast to ... The global oligonucleotide synthesis market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... the basis of products and services, applications, end users, ...
(Date:9/29/2014)... involve a range of resource and environmental problems. ... resin and a clever recycling strategy, Uppsala researchers ... alternative. Their study will be presented soon in ... think our discovery can open several doors to ... the future, says Daniel Brandell, Associate Professor at ...
Breaking Biology Technology:ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Smart, eco-friendly new battery to solve problems 2
... CAMBRIDGE, Mass., Jan. 13 Verenium Corporation,(Nasdaq: ... the development of next-generation cellulosic,ethanol and high-performance ... compliance with the continued listing requirements of ... that it had fallen out of,compliance with ...
... January 15th at 1:00PM PTNEW YORK, Jan. 13 ... announced that Michael S. Weiss, the Company,s Chairman and ... J.P. Morgan 27th Annual Healthcare Conference being held in ... Thursday, January 15th at 1:00pm PT and will be ...
... Jan. 13 Burnham Institute for Medical ... and license agreement with Johnson & Johnson ... The agreement is Burnham,s first broad-based partnership ... agreement, Burnham will provide J&JPRD with access ...
Cached Biology Technology:Verenium Regains Compliance With Nasdaq Continued Listing Requirement 2Verenium Regains Compliance With Nasdaq Continued Listing Requirement 3Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2
(Date:9/29/2014)... that the exposure to tar tended to be lower ... Similarly, exposure to nicotine tended to be lower. ... cigarette in several countries around the world. Previous studies ... in the smoke of these cigarettes are lower than ... chemicals in the smoke are not necessarily linked to ...
(Date:9/29/2014)... According to a NASA story from 2009, "human activities in ... fire emissions issue. Palm oil is increasingly grown for use ... fats in processed foods. It has become the most widely ... in recent years to surpass that of soybean oil. , ... has to be cleared to grow the crop, and the ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Slim cigarette smokers not exposed to more harmful chemicals 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... 2008The 2008 American Society for Microbiology (ASM) BD ... presented to Stephen C. Edberg, Professor, Department of ... of Medicine, and Director, Clinical Microbiology Laboratory, Yale-New ... award recognizes a distinguished scientist for research accomplishments ...
... be the first recipient of a prestigious award given by ... Meeting of the Ecological Society of America on August 3. ... an outstanding record of informing their political decision-making with ecological ... figure that has a sharp appreciation for local and global ...
... 28, 2008The 2008 American Society for Microbiology (ASM) ... is presented to Steven A. Rosenberg, Chief of ... Services University of the Health Sciences, and Professor ... and Health Sciences. Sponsored by Abbott Laboratories Diagnostics ...
Cached Biology News:American Society for Microbiology honors Stephen C. Edberg 2American Society for Microbiology honors Steven A. Rosenberg 2
Human SDNSF/MCFD2 Biotinylated Affinity Purified PAb...
... Nucleon HT, 1 kit. Facilitates the ... paraffin-embedded sections and hard tissue requiring proteinase ... high quality DNA from 50 preparations of ... Category: DNA/RNA Synthesis & Purification, Purification and ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Phospho-p70 S6 Kinase (T229) Affinity Purified PAb...
Biology Products: